Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ligand Pharmaceuticals

146.32
+3.922.75%
Pre-market: 148.211.89+1.29%05:36 EDT
Volume:300.22K
Turnover:43.76M
Market Cap:2.82B
PE:-20.58
High:149.21
Open:144.80
Low:140.00
Close:142.40
52wk High:149.21
52wk Low:92.04
Shares:19.29M
Float Shares:18.86M
Volume Ratio:1.54
T/O Rate:1.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1093
EPS(LYR):-0.2204
ROE:-16.56%
ROA:-1.14%
PB:3.55
PE(LYR):-663.74

Loading ...

Aug 07, 2025

Major Issues Report

Form 8-K - Current report
Aug 01, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 10, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 02, 2025

Major Issues Report

Form 8-K - Current report
Jun 23, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 10, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 09, 2025

Major Issues Report

Form 8-K - Current report
May 16, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 09, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 08, 2025

Major Issues Report

Form 8-K - Current report
Apr 17, 2025

Major Issues Report

Form 8-K - Current report
Mar 19, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 05, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 28, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 27, 2025

Major Issues Report

Form 8-K - Current report
Feb 25, 2025

Major Issues Report

Form 8-K - Current report
Dec 23, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 27, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 12, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 08, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]